What does HeartSciences do?
Two products, one modernization thesis
HeartSciences Inc. is a Nasdaq-listed healthcare information technology and medical-device company seeking to extend the standard electrocardiogram. Its thesis is that an ECG can become a digital input for clinical workflow and AI algorithms that screen for heart disease. The company describes this strategy on its official company overview.
| Element | Company-specific description | Why it matters |
|---|---|---|
| MyoVista Insights | Device-agnostic, cloud-native ECG management software designed to connect existing ECG equipment, hospital systems, and AI algorithms. | It can be deployed without replacing a health system's installed ECG fleet. |
| MyoVista wavECG | A proprietary 12-lead ECG device intended to provide conventional ECG functions and support on-device AI-enabled analysis. | It adds a vertically integrated route but requires clearance, manufacturing, and device-sales execution. |
| Customer base | Hospitals, integrated delivery networks, cardiology practices, and other clinical settings that acquire and interpret ECGs. | Health-system sales create long cycles and integration work, but also potential workflow stickiness. |
| Economic stage | Pre-scale commercialization with immaterial fiscal 2026 revenue and recurring operating losses. | The core questions are adoption and financing. |
Why the company matters despite tiny revenue
HeartSciences sits at the intersection of hospital software, regulated diagnostics, and algorithm commercialization. MyoVista Insights is classified as a Medical Device Data System, while diagnostic algorithms and wavECG can require separate regulatory pathways. This permits software commercialization before every diagnostic feature is cleared.
HeartSciences is neither a scaled device maker nor a mature software vendor. Its value depends on converting integration, regulatory assets, and intellectual property into repeatable contracts.
How does HeartSciences make money?
The SaaS and marketplace model
Management's preferred model is recurring software revenue. MyoVista Insights can combine a core hospital deployment with usage-based or per-test fees. HeartSciences then intends to offer its own and third-party AI-ECG algorithms. Hosting, licensing, and revenue-share terms will determine how much of each test's economics the company retains.
Commercial evidence arrived after fiscal year-end. HeartSciences announced a SaaS agreement with St. Vincent Health in May 2026, followed by another hospital agreement through the Cibolo Health network. The first SaaS agreement announcement matters because it tests implementation, clinical use, and reference-site credibility.
Which revenue stream could matter most?
| Revenue path | Pricing logic | Margin and cash-flow implication | Current evidence |
|---|---|---|---|
| Platform SaaS | Recurring contract and potentially usage-based fees. | Potentially attractive incremental margins after implementation, but early deployments require integration and support. | Initial hospital contracts announced in May 2026. |
| AI algorithm marketplace | Per-test fees, hosting, licensing, or revenue share. | Can expand revenue per ECG without hardware manufacturing; economics vary by partner. | Version 1.3 launched with the first FDA-cleared third-party algorithm in June 2026. |
| wavECG hardware | Device sales, placements, service, and associated software. | More capital-intensive than software, with regulatory and inventory risk. | FDA 510(k) submission disclosed in December 2025; clearance remained pending in the latest materials. |
| Licensing and partnerships | Negotiated licenses, development arrangements, and shared commercialization. | Reduces internal development burden but gives partners bargaining power. | Mount Sinai licenses and the Bunkerhill Health algorithm illustrate the partner-led model. |
For a DCF, the critical uncertainty is the adoption curve. Analysts need assumptions for deployed sites, ECG volume, revenue per test, algorithm attach rate, partner shares, and implementation expense. With an almost-zero base, small changes produce sharply different outcomes.
What do the latest financial reports show?
The latest annual snapshot
HeartSciences filed its fiscal 2026 Form 10-K on July 23, 2026. The official filing announcement confirms the report and continuing Fortitude process. The numbers show product-launch spending funded by equity and structured debt.
| Metric | Fiscal 2026 | Fiscal 2025 | Interpretation |
|---|---|---|---|
| Revenue | $4,319 | $0 | Commercialization began, but revenue was immaterial. |
| Research and development | $2.84M | $4.39M | Expense fell about 35% as platform work moved toward launch. |
| Selling, general and administrative | $5.58M | $3.97M | Commercialization, financing, and transaction activity raised overhead. |
| Net loss | $(9.14)M | $(8.77)M | Lower R&D was offset by SG&A and interest. |
| Operating cash used | $(7.43)M | $(7.41)M | Cash burn was nearly unchanged. |
| Cash at year-end | $1.66M | $1.10M | Financing lifted cash, but liquidity remained thin. |
What changed after the January quarter?
For the quarter ended January 31, 2026, HeartSciences reported no revenue, a $1.93M operating loss, a $1.99M net loss, $3.40M of cash, and $2.65M of equity. The January 2026 Form 10-Q shows that financing—not customer collections—created the cash peak.
At year-end, current assets were $2.58M against $4.86M of current liabilities, and equity had fallen to $0.23M. The current ratio was about 0.53 versus 1.19 at January 31. Growth potential therefore cannot be separated from working-capital pressure and financing access.
Which turning points shaped the current strategy?
Seven strategic turning points
The relevant history is the sequence that created today's intellectual property, commercial model, financing structure, and strategic redirection.
-
2007
The company was incorporated as Heart Test Laboratories, initially focused on ECG hardware and cardiac-dysfunction detection.
-
2022
The Nasdaq IPO created a financing channel while adding listing costs and dilution risk.
-
2023
Mount Sinai licenses expanded the portfolio across ventricular function, valve disease, pulmonary embolism, and cardiomyopathy.
-
2024
A 1-for-100 reverse split and the HeartSciences name reflected capital-market pressure and a broader platform identity.
-
March-April 2026
Epic Toolbox designation and full commercial launch made interoperability the main route into health systems.
-
May-June 2026
Initial SaaS contracts and an FDA-cleared marketplace algorithm created early commercial proof.
-
June 2026
The Fortitude transaction introduced an unrelated mining thesis and made merger completion central.
Electronic-health-record integration can determine whether a clinical product fits routine workflow. HeartSciences' Epic Toolbox designation announcement cites HL7v2, single sign-on, and SMART on FHIR capabilities that can reduce implementation friction.
AI-ECG interoperability is the central competitive thesis
Interoperability lowers the adoption hurdle
The strongest strategic feature is device agnosticism. Hospitals already own ECG fleets, so replacement creates budget, training, and procurement barriers. MyoVista Insights instead connects existing sources and delivers records and AI outputs through clinical systems, broadening the addressable installed base.
Workflow embedding could create switching costs, but that remains unproven. The company must demonstrate reliable deployment, clinical acceptance, cybersecurity, and measurable benefit at multiple sites.
Patents and licensed algorithms create optionality
The fiscal 2026 annual report describes nine U.S. utility patents, one U.S. design patent, and additional licensed and international rights, with U.S. expirations from 2031 to 2040. The portfolio supports proprietary methods and partner negotiations across several disease states.
The June 2026 launch of MyoVista Insights version 1.3 added the first FDA-cleared algorithm on the marketplace: Bunkerhill Health's ECG-EF tool for identifying reduced ejection fraction. The official version 1.3 announcement gives the marketplace a cleared, deployable third-party product.
Who competes with HeartSciences, and where is it positioned?
Scale asymmetry defines the competitive landscape
HeartSciences faces established ECG manufacturers—GE HealthCare, Philips, Baxter, and Nihon Kohden—and AI companies such as Anumana, Tempus, and Viz.ai. The first group has installed hardware and hospital relationships; the second competes for use cases, data, approvals, and integrations. HeartSciences identifies these rivals in its fiscal 2026 filing.
| Competitive group | Representative names cited by HeartSciences | Their advantage | HeartSciences response |
|---|---|---|---|
| Established ECG systems | GE HealthCare, Philips, Baxter, Nihon Kohden | Installed base, brand trust, field service, procurement relationships, and larger R&D budgets. | Integrate with existing equipment rather than requiring wholesale replacement. |
| AI-ECG specialists | Anumana | Focused algorithm development, clinical validation, and potential direct commercialization. | Offer a marketplace that can host multiple algorithms and potentially turn competitors into partners. |
| Broader clinical AI platforms | Tempus, Viz.ai | Capital, data, sales coverage, and established healthcare-AI positioning. | Concentrate on ECG workflow and point-of-care deployment rather than a broad diagnostic portfolio. |
The scorecard interprets official disclosures rather than providing an external rating. HeartSciences has a plausible integration and IP story but much less capital and implementation evidence than larger rivals. Partner power is material because algorithm developers can demand revenue share, exclusivity, or direct channels.
How financially strong is HeartSciences?
Liquidity depends on financing, not operations
HeartSciences is not self-sustaining. Fiscal 2026 operating cash use was $7.43M against $4,319 of revenue. Financing supplied $8.03M, while the accumulated deficit reached $85.27M, notes payable were $3.62M, and the working-capital deficit was $2.28M at April 30, 2026.
The January 2026 Streeterville note had $3.605M of document principal, a $600,000 original-issue discount, about $3.0M of net proceeds, 12% interest, and July 2027 maturity. Redemption features can add pressure if refinancing or equity issuance is unavailable.
How capital allocation reflects the development stage
| Use or source of capital | Fiscal 2026 fact | Analytical meaning |
|---|---|---|
| R&D | $2.84M | Investment shifted toward launch and commercialization, but regulatory and algorithm work remain necessary. |
| Capitalized software | $0.72M carrying value at April 30, 2026 | Some platform development is recognized as an asset; future value depends on commercial use and recoverability. |
| Series D financing | Approximately $6.7M gross proceeds | Extended runway but increased share count, preferred-security complexity, and potential dilution. |
| Debt exchange | 570,626 common shares issued for principal and accrued interest | Reduced an older liability by transferring economic ownership to the lender. |
| Dividends and repurchases | None reported | All available capital is needed for operations, development, listing costs, and strategic transactions. |
A conventional free-cash-flow calculation is insufficient because development is split between expensed R&D and capitalized software while operating cash flow is deeply negative. Analysts should estimate normalized gross profit, sales and support expense, regulatory investment, and external capital needed before breakeven. Dilution belongs inside the scenario.
Who owns HeartSciences stock, and how is it governed?
Economic ownership is dispersed
The 2026 proxy shows one vote per common share alongside Series C and Series D preferred securities. No founder or executive held majority control, so outside holders matter in votes on equity plans, capital structure, and the Fortitude transaction. The figures below come from the 2026 definitive proxy statement.
| Holder or group | Reported position | Combined voting power | Why it matters |
|---|---|---|---|
| Front Range Ventures | 115,310 common and 148,213 Series C shares | 2.8% | A meaningful preferred holder and historical financing counterparty, but not a controlling owner. |
| Andrew Simpson | 87,867 common and 6,117 Series C shares | 2.2% | CEO and chairman influence comes mainly from office, board leadership, and incentive awards rather than voting control. |
| Directors and executive officers as a group | 157,627 common and 8,597 Series C shares | 3.9% | Insider alignment exists, but outside shareholders retain decisive economic influence. |
The merger changes governance and incentives
A June 2026 filing disclosed 425,000 restricted shares for Simpson, subject to closing and vesting, plus a larger equity-plan reserve. These awards link compensation to completion but add dilution. Post-transaction ownership must also include preferred conversions, warrants, financing shares, and merger consideration.
The Fortitude merger creates a radically different valuation path
What the proposed transaction would change
On June 23, 2026, HeartSciences signed an all-stock transaction with Fortitude Mining. Closing is expected in the second half of 2026, subject to approvals and other conditions. The combined company is expected to use the Fortitude brand and proposed ticker TUDE, with mining as the primary business and MyoVista continuing inside the organization.
The merger Form 8-K and the accompanying official investor presentation describe the proposal; they do not assure closing. Voting, conditions, financing, ownership, and integration remain uncertain.
Why valuation becomes a scenario exercise
A MyoVista-only DCF now misses the dominant corporate event. One branch should model a delayed or failed close and continued medical-technology funding. A close case must incorporate exchange ratios, pro forma ownership, mining cash flow, power costs, capital expenditure, digital-asset exposure, and residual MyoVista funding.
| Driver | Standalone medical-technology case | Post-merger case | What to model |
|---|---|---|---|
| Revenue | Hospital sites, ECG volume, SaaS fees, and algorithm attach rates. | Mining output, realized digital-asset prices, hosting or infrastructure income, plus MyoVista. | Separate operating segments and avoid applying one growth rate to unrelated businesses. |
| Margins | Software gross margin less implementation, clinical support, regulatory, and sales expense. | Power cost, network difficulty, equipment efficiency, depreciation, and corporate overhead. | Use business-specific unit economics, not a blended target margin without evidence. |
| Reinvestment | Algorithm validation, regulatory submissions, integrations, and commercial staffing. | Mining equipment, data-center capacity, power infrastructure, and digital-asset strategy. | Forecast capital intensity and funding needs explicitly. |
| Discount rate and terminal risk | Early-stage adoption, reimbursement, regulatory, concentration, and dilution risk. | Commodity-like digital-asset volatility, regulation, technology obsolescence, and transaction integration. | Use scenario probabilities and a wider sensitivity range than for a mature public company. |
HeartSciences argues that the combination adds a scaled revenue business while MyoVista continues with greater focus. The counterpoint is complexity: medical diagnostics and mining have different capital cycles, risks, and valuation methods.
What risks and opportunities could change the story?
Commercial proof and capital availability are the near-term tests
The opportunity is to convert a ubiquitous test into a higher-value workflow and algorithm channel. The risk is insufficient time, capital, or market power before larger rivals and procurement barriers constrain adoption.
Other filing-based risks include physician acceptance, reimbursement, long sales cycles, IP disputes, key-person dependence, Nasdaq compliance, dilution, and algorithm underperformance. The Fortitude transaction adds closing, digital-asset price, energy-cost, mining-difficulty, equipment, regulatory, and integration risks.
What should researchers monitor, and what is the key takeaway?
A disciplined monitoring dashboard
HeartSciences is a milestone-and-financing case, not a historical-trend case. Each period should be tested against contracts, live sites, ECG volume, algorithm availability, revenue, gross economics, operating burn, and dilution.
- Reconcile contract announcements with reported revenue and accounts receivable.
- Separate platform software revenue from hardware, algorithm, and one-time implementation income.
- Track SG&A after merger-related costs and commercialization spending are disclosed separately.
- Measure cash runway using operating cash burn, debt redemptions, and committed transaction expenses.
- Update fully diluted share count for preferred conversions, warrants, restricted awards, equity lines, and merger consideration.
- Build standalone and transaction-close valuation cases until the Fortitude combination is completed or terminated.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.